Revaluation of Cerebrovascular Uses for Bronchial Asthma and Cerebrovascular Agent KETAS Capsules
December 20, 2001
Kyorin Pharmaceutical Co., Ltd. (Head office: Tokyo, President Ikuo Ogihara) has conducted post-launch, extraordinary clinical trials and submitted the results to the authorities for its bronchial asthma and cerebrovascular agent KETAS capsules 10 mg (Japanese generic name: Ibudilast). This activity comes in response to a government request to revaluate the efficacy in cerebrovascular Uses. According to a notification by the authorities to Kyorin Pharmaceutical today (December 20, 2001), the Drug Revaluation Commission convened on November 27, 2001 found improvements in efficacy for vertigo in patients with chronic cerebral circulation impairment associated with sequelae of cerebral infarction.
Adobe Reader software is required to view and print PDF files. The latest version of Adobe Reader can be downloaded by accessing the Adobe Systems Incorporated website.